S1P Receptor Modulator Therapy for ME/CFS Fatigue Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are currently no approved therapeutic drugs for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia, with existing treatments showing limited efficacy.
Innovation Solution
Development of therapeutic agents containing compounds such as amiselimod, ceralifimod, cenerimod, etrasimod, ozanimod, ponesimod, and siponimod, or their pharmaceutically acceptable salts, for treating and potentially preventing ME/CFS and fibromyalgia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutic interventions (SSRI, MAO inhibitors, Chinese herbal medicines) are used for ME/CFS, then some depressive symptoms and pain symptoms are alleviated, but only a small number of cases are examined and only a part of patients prove effective
Solution Approach 1:
The patent changes the pharmacological parameter by introducing a novel compound (amiselimod) with a different mechanism of action compared to existing SSRIs and MAO inhibitors. This compound demonstrates efficacy across a broader patient population by targeting different pathological pathways involved in ME/CFS, thereby improving both reliability and adaptability of treatment
2Adaptability or versatility
If no approved therapeutic drugs are available for ME/CFS, then patients have limited treatment options, but developing new drugs requires extensive research and validation
Solution Approach 1:
The patent performs preliminary action by conducting extensive preclinical studies and identifying amiselimod as a promising therapeutic agent before formal approval processes. The research includes evaluating the compound's efficacy in animal models and characterizing its pharmacological properties, thereby preparing the groundwork for future clinical development and reducing the complexity of the overall drug approval process
Data Source
AI summary
The present invention aims to provide a therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia. A therapeutic agent for a disease selected from myalgic encephalomyelitis/chronic fatigue syndrome, and fibromyalgia, containing 2-amino-2-[2-(4-heptyloxy-3-trifluoromethylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof.